Collegium Pharmaceutical reported second-quarter 2026 net revenues of $199.9 million, a 6% increase year-over-year, and updated its full-year financial guidance following the completion of its acquisition of AZSTARYS. JORNAY PM net revenue rose 41% to $46.1 million, while AZSTARYS contributed $12.9 million in net revenue from May 12 through June 30, representing a partial quarter of sales. The pain portfolio generated $140.9 million in net revenue, down 9% from the prior year, with Belbuca up 10% to $57.7 million, Xtampza ER down 14% to $45.0 million, and the Nucynta franchise down 24% to $35.2 million. The company lowered its full-year product revenue guidance to a range of $825 million to $855 million and adjusted EBITDA to $445 million to $470 million, citing lower-than-expected authorized generic pricing for Nucynta, while raising its AZSTARYS revenue outlook to $65 million to $75 million. GAAP net loss for the quarter was $15.1 million, or $0.46 per share, compared to net income of $12.0 million a year earlier, while non-GAAP adjusted net income rose to $75.4 million, or $1.92 per share, and adjusted EBITDA increased 8% to $113.8 million.
Collegium Pharmaceutical IncReports 6% revenue growth and raises AZSTARYS outlook, though lowers overall guidance due to Nucynta pricing.
